Drugs / Hyperforin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06617026 | Aug → Oct 2024 | ulcer of anus and rectum | Suez Canal University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07397325 Comparator | Apr → Oct 2026 expected | chemotherapy-induced alopecia, chemotherapy-induced toxicity | Applied Biology, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hyperforin | “the combination of azadirachtin and hyperforin (HyperOil®)” NCT06617026 ↗ |